Evidence mapPaperPMID 37341302Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes.

Yumin Wang, Shuang Wu, Qiang Li, Huiyan Sun, Hongquan Wang

Open access · goldAbstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 1 pooled it
34.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Targeting mCell proliferation · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yumin WangDepartment of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, P. R. China.ORCID 0000-0001-7023-7159
Shuang WuDepartment of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, 430000, P. R. China.
Qiang LiDepartment of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, 024005, P. R. China.
Huiyan SunChifeng University Health Science Center, Chifeng, 024000, P. R. China.
Hongquan WangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, P. R. China.ORCID 0000-0002-5447-2017
Chifeng University · CNPeking University · CNTianjin Medical University Cancer Institute and Hospital · CNWuhan University · CN

Funding

National Natural Science Foundation of China 81260196National Natural Science Foundation of China 81450036Natural Science Foundation of Inner Mongolia Autonomous Region 2020MS08175Natural Science Foundation of Inner Mongolia Autonomous Region 2021LHMS08024Natural Science Foundation of Inner Mongolia Autonomous Region 2022MS08046Science Foundation of AMHT 2020YK02Science Foundation of AMHT 2021YK05Science Foundation of AMHT 2022YK01Science Foundation of ASCH YN202104Science Foundation of ASCH YN202305Science Foundation of Inner Mongolia Key Laboratory of human genetic diseases YC202304Science Foundation of Inner Mongolia Key Laboratory of human genetic diseases YC202305
6 · The paper itself

Abstract

Emerging evidence suggests that ferroptosis, a unique regulated cell death modality that is morphologically and mechanistically different from other forms of cell death, plays a vital role in the pathophysiological process of neurodegenerative diseases, and strokes. Accumulating evidence supports ferroptosis as a critical factor of neurodegenerative diseases and strokes, and pharmacological inhibition of ferroptosis as a therapeutic target for these diseases. In this review article, the core mechanisms of ferroptosis are overviewed and the roles of ferroptosis in neurodegenerative diseases and strokes are described. Finally, the emerging findings in treating neurodegenerative diseases and strokes through pharmacological inhibition of ferroptosis are described. This review demonstrates that pharmacological inhibition of ferroptosis by bioactive small-molecule compounds (ferroptosis inhibitors) could be effective for treatments of these diseases, and highlights a potential promising therapeutic avenue that could be used to prevent neurodegenerative diseases and strokes. This review article will shed light on developing novel therapeutic regimens by pharmacological inhibition of ferroptosis to slow down the progression of these diseases in the future.

Indexed as

FerroptosisNeurodegenerative DiseasesStrokeCell DeathHumansAlzheimer's diseaseamyotrophic lateral sclerosisferroptosisintracerebral hemorrhageischemic strokeParkinson's diseasesubarachnoid hemorrhage

Identifiers

PMID37341302
PMCPMC10460905
OpenAlexW4381470107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.